(© Image: Depositphotos) - Inflammations of the peritoneum (peritonitis) are as frequent as they are feared complications in peritoneal dialysis, a form of kidney replacement therapy for independent use at home. The bacteria responsible for the life-threatening infections are becoming increasingly resistant to many antibiotics. A research team led by Markus Zeitlinger, Head of the Department of Clinical Pharmacology at MedUni Vienna, has now succeeded in identifying a new drug treatment option as part of a study. The research has just been published in the Clinical Microbiology and Infection journal. To attain their result, the researchers analysed blood samples and dialysis fluid from patients on peritoneal dialysis and applied computer-assisted simulation models. It became evident that a comparatively low dosage of the drug combination of ceftazidime and avibactam is sufficient to treat peritonitis. These substances belong to the group of antibiotics that are used particularly for certain (gram-negative) multi-resistant pathogens, such as those found in peritonitis.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
Your Benefits
- Access to all content
- Receive newsmails for news and jobs
- Post ads
